Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure-Activity Relationships and Molecular Docking.

Interleukin-6 (IL-6) is a proinflammatory cytokine that plays a key role in the pathogenesis and physiology of inflammatory and autoimmune diseases, such as coronary heart disease, cancer, Alzheimer's disease, asthma, rheumatoid arthritis, and most recently COVID-19. IL-6 and its signaling pathway are promising targets in the treatment of inflammatory and autoimmune diseases. Although, anti-IL-6 monoclonal antibodies are currently being used in clinics, huge unmet medical needs remain because of the high cost, administration-related toxicity, lack of opportunity for oral dosing, and potential immunogenicity of monoclonal antibody therapy.

A facile route to fabricate stable reduced graphene oxide dispersions in various media and their transparent conductive thin films.

In this paper, we demonstrate an easy way to prepare a stable reduced graphene oxide (RGO) dispersion in aqueous or organic media by simple adjustment of the degree of reduction and pH of RGO dispersion, and a subsequent fabrication of transparent conductive RGO thin films on various substrates using a spray coating technique. RGOs were prepared using a hydrazine reducing agent from graphene oxide (GO), which was oxidized from graphite via a modified Hummers' method. The degree of reduction determined the surface properties, such as atomic composition, surface polarity, and potential of RGO platelets.